NCT06274411 Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention
| NCT ID | NCT06274411 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Anzhen Hospital |
| Condition | ECMO |
| Study Type | INTERVENTIONAL |
| Enrollment | 176 participants |
| Start Date | 2025-03-21 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 176 participants in total. It began in 2025-03-21 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is : • If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI
Eligibility Criteria
Inclusion Criteria: 1. Clinicians decide to perform PCI during ECMO support. 2. Age of ≥18 3. Patient presents with a compromised ejection fraction of less than 35% or at risk of hemodynamic deterioration, or intervention on the last patent coronary conduit or an unprotected left main artery, or complex 3-vessel disease (SYNTAX score of ≥33) 4. Informed consent Exclusion Criteria: 1. Subject in cardiogenic shock(need inotrope, pressor or mechanical support to maintain SBP \>90mmHg) 2. Presence of moderate to severe aortic insufficiency 3. Severe peripheral vascular disease 4. creatinine≥4mg/dL 5. Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x ULN 6. History of recent (within 1 month) stroke or TIA 7. Abnormal coagulation(defined as platelet count ≤50000/mm3 or Fibrinogen ≤1.50g/L) 8. Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors, or documented heparin induced thrombocytopenia.
Contact & Investigator
Xiaotong Hou, MD
PRINCIPAL INVESTIGATOR
Beijing Anzhen Hospital
Frequently Asked Questions
Who can join the NCT06274411 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ECMO. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06274411 currently recruiting?
Yes, NCT06274411 is actively recruiting participants. Contact the research team at xt.hou@ccmu.edu.cn for enrollment information.
Where is the NCT06274411 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06274411 clinical trial?
NCT06274411 is sponsored by Beijing Anzhen Hospital. The principal investigator is Xiaotong Hou, MD at Beijing Anzhen Hospital. The trial plans to enroll 176 participants.